U.S. Stock News

NYSE:ETSY
NYSE:ETSYMultiline Retail

Etsy PrintKK Partnership Puts AI And Automation At Center Stage

PrintKK has launched a global, integrated print on demand solution for Etsy sellers, adding automation and AI powered design tools. The integration gives sellers access to a wide range of customizable products and automated fulfillment aimed at international buyers. This development introduces new ways for Etsy merchants to test products without holding inventory and could influence the variety of items available on the marketplace. Etsy, listed on the NYSE under ticker NYSE:ETSY, is...
NasdaqGS:TBLA
NasdaqGS:TBLAInteractive Media and Services

Taboola.com (TBLA) Valuation Check After Swing To Profit And New Revenue Guidance

Why Taboola.com (TBLA) is back on investor radar Taboola.com (NasdaqGS:TBLA) is in focus after reporting fourth quarter and full year 2025 results that shifted from a prior year net loss to net income, along with new 2026 revenue guidance. See our latest analysis for Taboola.com. The earnings release and fresh 2026 guidance have put Taboola.com back in focus, with a 1 day share price return of 6.92% and 7 day share price return of 11.11% contrasting with a weaker year to date share price...
NYSE:ACA
NYSE:ACAConstruction

Arcosa Refocuses On Infrastructure As Barge Sale Reshapes Earnings Story

Arcosa (NYSE:ACA) announced the sale of its barge business and is shifting its focus toward construction materials and engineered structures. The move is aimed at concentrating resources on U.S. infrastructure and power related businesses that management views as core to the company. Arcosa, trading at $111.28 at the last close, is coming off a strong longer term stretch, with the stock up 37.0% over the past year and 87.8% over three years. The company is also ahead 76.5% over five years,...
NYSE:LTH
NYSE:LTHHospitality

Life Time Group Launches US$500m Buyback As Valuation Signals Diverge

Life Time Group Holdings (NYSE:LTH) has approved a new $500 million share repurchase program. The buyback plan targets the company's common stock and is intended to support long term shareholder value. This authorization adds a fresh capital allocation lever for the fitness and lifestyle operator. Life Time Group Holdings, trading at $26.12 per share, is coming off a mixed share price run, with a 51.2% gain over three years but a 13.3% decline over the past year. In the shorter term, the...
NasdaqGS:PGNY
NasdaqGS:PGNYHealthcare

Progyny Adds INVO Fertility Clinic As Network Grows And Shares Lag

INVO Fertility has joined the Progyny (NasdaqGS:PGNY) provider network, adding its clinic to Progyny's fertility benefits platform. The partnership expands access to employer sponsored fertility care for patients in Wisconsin and nearby regions. This development broadens Progyny's provider footprint and increases potential touchpoints with covered employees seeking fertility treatment. Progyny runs a fertility benefits platform that connects employer sponsored health plans with a network of...
NYSE:MPT
NYSE:MPTHealth Care REITs

Medical Properties Trust Faces Prospect Bankruptcy Test For Rent Resilience

Medical Properties Trust (NYSE:MPT) has issued a response to Prospect Medical Group's bankruptcy filing. The company is outlining potential operational impacts related to Prospect's tenant status and leased hospital assets. Investors are watching for updates on rental income exposure, asset utilization, and any changes to existing lease arrangements. Medical Properties Trust focuses on owning and leasing hospital and healthcare facilities, so any disruption involving a key tenant like...
NasdaqGS:AARD
NasdaqGS:AARDPharmaceuticals

A Look At Aardvark Therapeutics (AARD) Valuation After HERO Trial Pause And Volatile Share Price Moves

Aardvark Therapeutics (AARD) has put its Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome on hold after reversible cardiac issues at higher doses, triggering delays, legal scrutiny, and sharp share price swings. See our latest analysis for Aardvark Therapeutics. The HERO trial pause has been the clear driver of volatility, with Aardvark Therapeutics’ 1-day share price return of 15.1% coming after sharp declines, including a 57.6% 30-day share price loss and a 50.4% 1-year total...
NYSE:KVUE
NYSE:KVUEPersonal Products

Institutional Exit Tests Kenvue’s Valuation, Dividend Strength And Momentum

SCCM Enhanced Equity Income Fund has fully exited its position in Kenvue (NYSE:KVUE). The decision highlights ongoing business challenges, including US consumer spending pressures and delayed seasonality in key product lines. Operational headwinds in China, rising competition, and market share erosion are central to current investor concerns. Kenvue, trading at $18.19, is drawing fresh attention after the SCCM Enhanced Equity Income Fund chose to exit its position entirely. The stock is up...
NYSE:SEMR
NYSE:SEMRSoftware

Semrush AI Push With Spotlight 2026 And ChatGPT Integration Under Adobe Deal

Semrush Holdings (NYSE:SEMR) has launched Spotlight 2026, an AI focused marketing conference centered on brand visibility in the AI search era. The company has introduced an official Semrush app within ChatGPT to bring its marketing toolkit into the conversational AI environment. These moves come as Semrush continues through its planned acquisition process with Adobe. Semrush operates as a digital marketing platform, with tools that help businesses manage search visibility, content, and...
NasdaqGS:ROOT
NasdaqGS:ROOTInsurance

Does Root’s (ROOT) Strong 2025 Results but Softer Q4 Profit Reframe Its Profitability Story?

Root, Inc. previously reported fourth-quarter 2025 revenue of US$397 million, up from US$326.7 million a year earlier, with net income of US$5.1 million compared with US$20.9 million. For 2025 overall, Root lifted revenue to US$1.52 billion and increased net income to US$38.3 million, but its fourth-quarter profit was lower than the prior year despite higher sales. Next, we’ll examine how Root’s higher full-year revenue and earnings, alongside weaker quarterly profit, may influence its...
NYSE:INSW
NYSE:INSWOil and Gas

International Seaways Supplemental Dividend Puts Cash Returns And Valuation In Focus

International Seaways (NYSE:INSW) has announced a major supplemental dividend to be paid alongside its regular quarterly dividend. The Board of Directors approved the additional payout, signaling a significant return of capital to shareholders. The decision reflects management's view of the company’s current financial position and cash resources. International Seaways focuses on crude and product tanker shipping, a segment that tends to be closely linked to global energy trade and fleet...
NasdaqCM:HYMC
NasdaqCM:HYMCMetals and Mining

Hycroft Mining Reset Puts Larger Resources And Funding Needs In Focus

Hycroft Mining Holding (NasdaqCM:HYMC) reports a 55% increase in its gold and silver mineral resource base. The company eliminates all debt and shifts its focus from production to exploration and development. Hycroft launches its largest exploration drill program to date. The stock is added to the MSCI Small Cap Index, increasing its visibility with institutional investors. Hycroft Mining Holding, trading at $47.665, has gone through a major reset that is drawing fresh attention from the...
NYSE:YETI
NYSE:YETILeisure

New YETI CFO From Home Depot May Reshape Growth And Capital Choices

YETI Holdings (NYSE:YETI) has appointed Scott Bomar as its new Chief Financial Officer. Bomar joins the company from The Home Depot, bringing financial and operational leadership experience. He succeeds long serving CFO Mike McMullen, marking a key change in YETI's executive team. YETI Holdings, known for its premium coolers, drinkware and outdoor gear, sits at the intersection of consumer brands and the broader outdoor recreation and lifestyle market. For investors watching branded...
NasdaqGS:OMCL
NasdaqGS:OMCLMedical Equipment

Omnicell Leans Into Healthcare IT As ANiGENT Deal Reshapes Growth Story

Omnicell, ticker NasdaqGS:OMCL, is shifting its focus toward a software and services led model. The company recently acquired ANiGENT to deepen its capabilities in drug diversion detection within healthcare settings. This move marks a meaningful step in Omnicell's transition from a hardware vendor to a Healthcare IT company. Omnicell's pivot comes after a mixed share price record, with the stock at $41.53 and a value score of 4. The shares show a 9.8% gain over the past year, while longer...
NasdaqGM:STAA
NasdaqGM:STAAMedical Equipment

STAAR Surgical (STAA) Posts US$80.4 Million Annual Loss Testing Turnaround Narratives

STAAR Surgical FY 2025 earnings snapshot STAAR Surgical (STAA) has wrapped up FY 2025 with Q4 revenue of US$57.8 million and a basic EPS loss of US$0.37, keeping the focus firmly on the path back to profitability. The company has seen quarterly revenue range from US$42.6 million to US$94.7 million since the start of 2024, while basic EPS has swung between a loss of US$1.10 and a profit of US$0.20. This sets up a mixed picture on margins that investors may view as an ongoing turnaround story...
NasdaqGS:EYE
NasdaqGS:EYESpecialty Retail

Same Store Sales Strength Tests Profitability Concerns At National Vision Holdings (EYE)

National Vision Holdings (EYE) has put up a mixed FY 2025 scorecard so far, with Q3 revenue at US$487.3 million, basic EPS of US$0.04 and same store sales growth of 7.7%, set against a trailing twelve month loss of US$3.2 million and basic EPS of roughly US$0.04 loss. Over recent quarters the company has seen revenue range from US$451.7 million in Q2 2024 to US$510.3 million in Q1 2025. Basic EPS has moved from a Q4 2024 loss of US$0.37 per share to a Q1 2025 profit of US$0.18 per share and...
NYSE:ACEL
NYSE:ACELHospitality

Accel Entertainment (ACEL) Margin Improvement Challenges Bears Focused On Concentration Risks

Accel Entertainment (ACEL) has wrapped up FY 2025 with fourth quarter revenue of US$341.4 million and EPS of US$0.19, capping a year in which trailing twelve month revenue reached US$1.3 billion and EPS came in at US$0.61. The company has seen quarterly revenue move from US$302.2 million in Q3 2024 to US$341.4 million in Q4 2025, while quarterly EPS stepped up from US$0.06 to US$0.19 over the same stretch, setting the backdrop for investors focused on earnings growth and profit consistency...
NasdaqGS:CRWD
NasdaqGS:CRWDSoftware

CrowdStrike (CRWD) First Profitable Quarter Challenges Trailing Loss Narrative

CrowdStrike Holdings (CRWD) FY 2026 results in focus CrowdStrike Holdings (CRWD) has capped FY 2026 with fourth quarter revenue of about US$1.3 billion and basic EPS of US$0.15, alongside trailing twelve month revenue of roughly US$4.8 billion and a trailing basic EPS loss of US$0.65. The company has seen quarterly revenue move from US$1.06 billion in Q4 FY 2025 to US$1.31 billion in Q4 FY 2026, while basic EPS shifted from a loss of US$0.37 to a profit of US$0.15 over the same periods. For...
OTCPK:FTCO
OTCPK:FTCOMetals and Mining

Fortitude Gold (OTCPK:FTCO) Q3 Profit Challenges Bearish Loss Narratives

Fortitude Gold (FTCO) has reported its FY 2025 third quarter with revenue of US$4.7 million, basic EPS of US$0.0096 and net income of US$0.2 million. Trailing 12 month figures sit at US$25.4 million in revenue and a net loss of US$0.5 million with basic EPS at US$0.021. Over recent quarters in FY 2025, revenue has moved from US$6.5 million in Q1 to US$4.9 million in Q2, and EPS has shifted from US$0.0517 in Q1 to US$0.0350 in Q2. Together, these figures give a clearer sense of how the income...
NasdaqGM:EYPT
NasdaqGM:EYPTPharmaceuticals

Is It Too Late To Consider EyePoint (EYPT) After A 1‑Year Surge And DCF Upside?

If you are wondering whether EyePoint's share price still reflects fair value after a strong run, you are not alone. This article is here to help you size that up clearly. The stock last closed at US$18.00, with returns of 1.4% over 7 days, 35.4% over 30 days, 3.0% year to date, 173.6% over 1 year, a gain of around 7x over 3 years, and 72.2% over 5 years. Recent news coverage around EyePoint has focused on its position in ophthalmology and its pipeline, which has kept investor attention on...
NYSE:BGS
NYSE:BGSFood

B&G Foods (BGS) TTM Loss Of US$43.3 Million Tests Bullish Turnaround Narratives

B&G Foods FY 2025 Results: Weak EPS, Soft Margins Keep Profitability Under Pressure B&G Foods (BGS) has capped FY 2025 with fourth quarter revenue of US$539.6 million and a basic EPS loss of US$0.19, keeping the full year in loss-making territory. The company has seen quarterly revenue move from US$551.6 million in Q4 2024 to US$539.6 million in Q4 2025. Basic EPS shifted from a Q4 2024 loss of US$2.81 to a Q4 2025 loss of US$0.19, and trailing twelve month EPS for Q4 2025 stands at a loss of...
NasdaqCM:SSTI
NasdaqCM:SSTISoftware

SoundThinking (SSTI) Posts Q4 Loss As Margins Keep Bullish Turnaround Narratives Under Pressure

SoundThinking (SSTI) has just closed out FY 2025 with fourth quarter revenue of US$24.8 million and a basic EPS loss of US$0.22, capping a trailing twelve month run of US$104.1 million in revenue and a total EPS loss of US$0.74. Over the past year, the company has reported quarterly revenue between US$24.8 million and US$28.3 million, while quarterly basic EPS has ranged from a loss of US$0.12 to US$0.25. This sets up a results season in which investors may pay less attention to changes in...
NYSE:PSFE
NYSE:PSFEDiversified Financial

Paysafe Q4 Loss Extends Unprofitable Trend And Tests Bullish Profitability Narratives

Paysafe (PSFE) has wrapped up FY 2025 with fourth quarter revenue of US$438.4 million and a basic EPS loss of US$0.45, alongside trailing 12 month revenue of about US$1.7 billion and a basic EPS loss of US$3.14. Over recent periods, the company has seen quarterly revenue move between US$401 million and US$438.4 million, while quarterly basic EPS has ranged from a loss of US$1.52 to a loss of US$0.33. This sets up a mixed picture on profitability that investors will be weighing against the...
NasdaqGS:ANAB
NasdaqGS:ANABBiotechs

AnaptysBio (ANAB) Q4 Profit Of US$49.6 Million Tests Longstanding Loss-Making Narrative

AnaptysBio's FY 2025 Headline Numbers AnaptysBio (ANAB) has put up a sharp swing in its latest quarter, with Q4 FY 2025 revenue at US$108.2 million and basic EPS of US$1.79, compared with a loss in the same quarter a year earlier and a trailing twelve month basic EPS of US$0.46 loss on revenue of US$234.6 million. Over recent periods, the company has seen quarterly revenue move from US$43.1 million in Q4 2024 to US$22.3 million in Q2 2025 and US$76.3 million in Q3 2025 before reaching...